Study summary · research use only
Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This mouse study compared chromosome aberration incidence in bone marrow cells of 12-month-old senescence-accelerated SAMP-1 female mice, wild-type SAMR-1 females, and SHR females. Incidence in SAMP-1 mice was 1.8 times higher than SAMR-1 and 2.2 times higher than SHR mice of the same age. Epithalon treatment starting at age 2 months was associated with decreased chromosome aberration incidence in SAMP-1, SAMR-1, and SHR mice by 20%, 30.1%, and 17.9% respectively, versus age-matched controls. Melatonin, given in drinking water at 20 mg/liter during night hours, showed no association with aberration incidence in SHR mice. The authors describe this as an antimutagenic association for Epithalon.
Abstract
The incidence of chromosome aberrations in bone marrow cells of 12-month-old SAMP-1 female mice characterized by accelerated aging was 1.8 times higher than in wild-type SAMR-1 females and 2.2 times higher than in SHR females of the same age. Treatment with Epithalon (Ala-Glu-Asp-Gly) starting from the age of 2 months decreased the incidence of chromosome aberrations in SAMP-1, SAMR-1, and SHR mice by 20%, 30.1%, and 17.9%, respectively, compared to age-matched controls (p<0.05). Treatment with melatonin (given with drinking water in a dose of 20 mg/liter in night hours) had no effect on the incidence of chromosome aberrations in SHR mice. These data indicate antimutagenic effect of Epithalon, which probably underlies the geroprotective effect of this peptide.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.